TRV GP Iv, LLC

In its 13F for Q3 2025 (holdings as of September 30, 2025, filed November 13, 2025), TRV GP Iv, LLC reported 2 stock positions worth $274.0 million. Its top holding was Maze Therapeutics (MAZE) at 57.5% of the portfolio, followed by Tango Therapeutics (TNGX, 42.5%). Compared with Q2 2025, it sold out of 1 and reduced 1. The biggest sale was Tango Therapeutics (TNGX, shares −18%).

Most Recent 13F
Q2 2026
Location
Boston, MA
CIK
0001688325
Portfolio Value
$274.0M (Q3 2025)
SEC Filing
0001193125-25-280198 ↗ filed Nov 13, 2025

Holdings Value

0$100.0M$200.0M$300.0M Q1 2024: $206.4M Q1 2024 Q2 2024: $202.2M Q2 2024 Q3 2024: $162.1M Q3 2024 Q4 2024: $80.2M Q4 2024 Q1 2025: $92.9M Q1 2025 Q2 2025: $163.3M Q2 2025 Q3 2025: $274.0M $274.0M Q3 2025 Q4 2025: $255.1M Q4 2025 Q1 2026: $266.9M Q1 2026 Q2 2026: $253.7M Q2 2026

Holdings 2 stocks · $274.0M
MAZE Maze Therapeutics Inc. 57.49% 6,073,958 $157.5M No change
TNGX Tango Therapeutics Inc. 42.51% 13,863,975 $116.5M Reduce -17.8%

Portfolio Sells Q2 2025 → Q3 2025
TNGX Tango Therapeutics Inc. Reduce -17.8% 42.51% −10.34
PLRX Pliant Therapeutics Inc. Sold out 0.00% −1.51

Portfolio Buys Q2 2025 → Q3 2025
None this quarter.

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 2$253.7MMAZE, TNGX
Q1 2026 2$266.9MMAZE, TNGX
Q4 2025 2$255.1MMAZE, TNGX
Q3 2025 2$274.0MMAZE, TNGX
Q2 2025 3$163.3MTNGX, MAZE, PLRX
Q1 2025 3$92.9MMAZE, TNGX, PLRX
Q4 2024 2$80.2MTNGX, PLRX
Q3 2024 3$162.1MTNGX, PLRX, FULC
Q2 2024 3$202.2MTNGX, PLRX, FULC
Q1 2024 3$206.4MTNGX, PLRX, FULC